| Literature DB >> 32281110 |
Jin-Jin Zhang1, Yi-Yuan Cao2, Xiang Dong1, Bin-Chen Wang2, Mei-Yan Liao2, Jun Lin3, You-Qin Yan4, Cezmi A Akdis5, Ya-Dong Gao1.
Abstract
Entities:
Mesh:
Year: 2020 PMID: 32281110 PMCID: PMC7262033 DOI: 10.1111/all.14316
Source DB: PubMed Journal: Allergy ISSN: 0105-4538 Impact factor: 13.146
Figure 1Number of patients testing positive for SARS‐CoV‐2 and the cumulative positive ratio at different rRT‐PCR tests. A, Changes in the outcome of the rRT‐PCR test of patients, from negative to positive, after consecutive assays. Of the 41 patients with an initial negative result, 21, 13, 4, 2, and 1 patients were tested positive at the 2nd, 3rd, 4th, 5th, and 6th rRT‐PCR assays, respectively. The cumulative positive rRT‐PCR assay ratio from the second to the fifth test increased from 51.2% (21/41) to 97.6% (40/41). B, Number and percentage of positive results within the total patient population. The cumulative positive ratio of all 290 patients from the first to the fifth test increased from 85.9% (249/290) to 99.7% (289/290). rRT‐PCR, real‐time reverse transcription–polymerase chain reaction
Demographics and partial clinical data of patients with COVID‐19
| All Patients (n = 290) | Initial result of SARS‐CoV‐2 rRT‐PCR test | |||
|---|---|---|---|---|
| Positive (n = 249) | Negative (n = 41) |
| ||
| Age—median (range) | 57 (22‐88) | 57 (22‐88) | 51 (22‐79) | .089 |
| Age groups ‐No. (%) | ||||
| <30 y | 16 (5.5) | 11 (4.4) | 5 (12.2) | .165 |
| 30‐49 y | 90 (31.0) | 76 (30.5) | 14 (34.1) | ‐ |
| 50‐69 y | 120 (41.4) | 107 (43) | 13 (31.7) | ‐ |
| ≥70 y | 64 (22.1) | 55 (22.1) | 9 (22.0) | ‐ |
| Sex—No. (%) | ||||
| Female | 135 (46.6) | 110 (44.2) | 25 (61.0) | .062 |
| Male | 155 (53.4) | 139 (55.8) | 16 (39.0) | ‐ |
| Exposure History—No. (%) | ||||
| Yes | 83 (28.6) | 74 (29.7) | 9 (22.0) | .308 |
| No | 207 (71.4) | 175 (70.3) | 32 (78.0) | ‐ |
| Comorbidity—No. (%) | 178 (61.4) | 158 (63.5) | 20 (48.8) | .074 |
| Hypertension | 81 (27.9) | 68 (27.3) | 13 (31.7) | .561 |
| Diabetes mellitus | 27 (9.3) | 25 (10) | 2 (4.9) | .393 |
| Coronary heart disease | 18 (6.2) (6.2) | 18 (7.2) | 0 (0.0) | .087 |
| Drug hypersensitivity (self‐reported) | 10 (3.4) | 10 (4.0) | 0 (0.0) | .367 |
| COPD | 6 (2.1) | 6 (2.4) | 0 (0.0) | .600 |
| Urticaria | 2 (0.7) | 1 (0.4) | 1 (2.4) | .263 |
| Asthma | 1 (0.3) | 1 (0.4) | 0 (0.0) | >.999 |
| Others | 72 (24.8) | 66 (26.5) | 6 (14.6) | .103 |
| Surgery history—No. (%) | 89 (30.7) | 82 (32.9) | 7 (17.1) | .041 |
| Tumor surgery | 15 (5.2) | 15 (6.0) | 0 (0.0) | .141 |
| Craniocerebral surgery | 6 (2.1) | 6 (2.4) | 0 (0) | .600 |
| Cardiac intervention | 10 (3.4) | 10 (4.0) | 0 (0) | .367 |
| Others | 62 (21.4) | 55 (22.1) | 7 (17.1) | .468 |
| Smokers—No. (%) | 28 (9.7) | 25 (10) | 3 (7.3) | .778 |
| Past Smokers | 18 (6.2) | 16 (6.4) | 2 (4.9) | >.999 |
| Current Smokers | 10 (3.4) | 9 (3.6) | 1 (2.4) | >.999 |
| Severity—No. (%) | ||||
| Severe | 121 (41.7) | 111 (44.6) | 10 (24.4) | .015 |
| Nonsevere | 169 (58.3) | 138 (55.4) | 31 (75.6) |
|
COVID‐19, coronavirus disease 2019; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2; rRT‐PCR, real‐time reverse transcription–polymerase chain reaction; COPD, chronic obstructive pulmonary disease; P values denote the statistical significance between initially positive and negative result subgroups.